Review Article

Kiwifruit and Kiwifruit Extracts for Treatment of Constipation: A Systematic Review and Meta-Analysis

Mohamed Eltorki 1, Russell Leong 2, and Elyanne M. Ratcliffe 3

1 Pediatric Emergency Physician, McMaster Children's Hospital, Department of Pediatrics, McMaster University, Hamilton, ON, Canada
2 Faculty of Health Sciences, Department of Pediatrics, McMaster University, Hamilton, ON, Canada
3 Pediatric Gastroenterology Physician, McMaster Children's Hospital, Department of Pediatrics, McMaster University, Hamilton, ON, Canada

Correspondence should be addressed to Mohamed Eltorki; eltorkim@mcmaster.ca

Received 19 January 2022; Accepted 18 August 2022; Published 6 October 2022

Academic Editor: Xingshun Qi

Copyright © 2022 Mohamed Eltorki et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Introduction. This systematic review aimed to summarize evidence to determine the effectiveness of kiwifruit or kiwifruit extracts in the treatment of constipation. Methods. Electronic databases were searched from inception to May 2022 without any age or language limitations. Eligible studies enrolled participants with constipation who were randomized to receive kiwifruit or kiwifruit extracts vs. any nonkiwifruit control. Standardized mean difference (SMD) and mean difference (MD) with confidence intervals (CI) were determined for the following outcomes: frequency of spontaneous bowel movements (SBM), abdominal pain and straining, as well as stool type as determined by the Bristol Stool Scale (BSS). The Grading of Recommendations, Assessment, Development and Evaluations (GRADE) approach was used to rate the certainty of evidence. Our review was registered on PROSPERO (CRD42021239397).

Results. Seven RCTs, including 399 participants (82% female; mean age: 42 years (SD 14.6)), were included. Compared with placebo (n = 95), kiwifruit extracts might increase the weekly frequency of SBM (MD: 1.36; 95% CI: −0.44, 3.16) with low certainty of evidence; moreover, it had an uncertain effect on BSS (SMD: 1.54; 95% CI: −1.33, 4.41) with very low certainty of evidence. Additionally, compared with placebo (n = 119), kiwifruit or its extracts reduced abdominal pain (SMD: −1.44, 95% CI: −2.83, −1.66) with moderate certainty of the evidence and improved frequency of straining (SMD: −0.29; 95% CI: −1.03, 0.47). Compared with psyllium, kiwifruit may increase the weekly frequency of SBM (MD: 1.01; 95% CI: −0.02, 2.04) with moderate certainty evidence, and may increase the value on the BSS (indicating softer stools) (MD: 0.63; 95% CI: 0.01, 1.25) with low certainty of evidence. Compared to placebo, kiwifruit-encapsulated extracts may result in an increase in minor adverse events (relative risk: 4.58; 95% CI: 0.79, 26.4). Conclusions. Among individuals with constipation, there is an overall low certainty of evidence indicating that kiwifruit may increase SBM when compared to placebo or psyllium. Although overall results are promising, establishing the role of kiwifruit in constipation requires large, methodologically rigorous trials. Protocol Registration: PROSPERO registration number CRD42021239397.

1. Introduction

Chronic constipation represents a significant health burden, with a global prevalence of 14%. In North America, constipation affects 35 million Americans, with mounting economic costs related to treatments and work absenteeism. [1–5] In the UK, it affects 1 in 7 adults and 1 in 3 children, resulting in over 200,000 primary care appointments per week and an annual rise in health care costs. In 2018, the UK estimated £162 million was spent on constipation-related clinical care annually, with £87 million spent on laxatives. [6].

The two most common presentations of constipation are functional constipation (FC) and irritable bowel syndrome with constipation (IBS-C), both of which are diagnosed based on the Rome consensus clinical criteria. [7] According
to Rome IV criteria, both FC and IBS-C are characterized by a decrease in the frequency of spontaneous bowel movements (SBM), a change in the appearance and consistency of stool based on the Bristol Stool Scale (BSS) [7], and straining with defecation, with abdominal pain being more predominant in IBS-C [7].

Current common treatments for FC and IBS-C include osmotic and stimulant laxatives, fibre supplements, and probiotics. [8, 9] While most pharmacological therapies studied are superior to placebo, [8] many patients report dissatisfaction with traditional treatment options and concerns related to efficacy and safety [10]. Increasingly, patients across the age spectrum are seeking alternative, more “natural,” nonpharmacological options, with the medical community responding with increased interest in the potential benefits of food or food extracts on functional gastrointestinal disorders [11–15].

There has been increasing global recognition of kiwifruit or kiwifruit extracts being beneficial for chronic constipation management, with a growing body of literature, including the publication of several randomized controlled trials (RCTs) [16–34]. The laxative effects of kiwifruit on patients with constipation seem to be related to a combination of high fibre and water content as well as an enzyme called actinidin. Additionally, kiwifruit may improve gastrointestinal motility through the enhancement of gastric emptying and protein digestion by actinidin, as well as changes to the gut microflora and increased motility through protease-activated signaling [27]. Companies are now producing chewable capsules from freeze-dried kiwifruit that contain actinidin, plant polyphenols, dietary fibre, carbohydrates, and oligosaccharides.

While data from healthy nonconstipated volunteers has been shown to be encouraging, our research question focused on the treatment of constipation with kiwifruit or kiwifruit extracts. Specifically, our research question addressed if kiwifruit or kiwifruit extracts improve outcomes in participants who have chronic constipation, such as FC and IBS-C, including improvements in bowel movement frequency, consistency, straining, and associated abdominal pain. We aimed to summarize and critically appraise the current evidence to determine the effectiveness and safety of kiwifruit or kiwifruit extracts on the symptoms of constipation in all age groups.

2. Methods

2.1. Selection of Studies. Study eligibility criteria are outlined in Table 1. We did not employ restrictions on participant age, specific diagnosis type, or language. Our outcomes are consistent with prior published trials and systematic reviews on treatments of FC [35–38] and the core outcome sets developed and endorsed by the Rome foundation for conducting clinical trials [39, 40]. Those included (1) weekly frequency of SBM (defined as a bowel movement that is spontaneous without any rescue laxatives, suppositories, enemas, or other physical assistance and leaves a feeling of complete evacuation); (2) Rome diagnostic criteria for FC or IBS-C measured at baseline and at follow-up (time of primary outcome is assessed); (3) stool consistency according to the BSS (scale range is 1–7: 1 is hardest stools and 7 is diarrhea); (4) proportion of bowel urgency or tenesmus; (5) frequency of straining with bowel movement; (6) frequency of rescue laxatives use; (7) relief of abdominal pain; (8) adverse events reported (e.g., bloating, nausea, vomiting, and allergic reactions).

Citations identified through the initial search were uploaded to a web-based systematic review management software (Covidence © 2021). [41] Using a piloted abstract screening sheet, identified abstracts were reviewed by two authors (M. E., R. L.) independently and in duplicate. Any abstract of a randomized trial that indicated the use of kiwifruit for constipation was included for full-text review. Using a piloted study selection sheet, two authors (M. E., R. L.) independently and in duplicate assessed the studies for eligibility after reading the full texts. Disagreement among authors was discussed and resolved by consensus, with a third reviewer (E. R.) acting as an arbitrator if necessary (Figure 1: PRISMA flowchart). We registered our systematic review prior to commencing the search (PROSPERO registration number CRD42021239397).

2.2. Search Methods for Identification of Studies. Our search strategy was developed with assistance from a medical librarian. A computer-assisted search for relevant studies (from database inception to May 18, 2022) was performed using MEDLINE, Embase, Web of Science, CINAHL, and Cochrane Library (S1: Supplement Digital Content). References from published articles and conference proceedings were hand-searched to identify any additional citations. Abstracts were included in our search if there was a corresponding full article or if enough information was in the abstract. For abstracts without a full article, we contacted the authors for the publishing status of the full article.

2.3. Data Extraction and Management. A data extraction form was developed and piloted on one RCT to extract information on relevant features and results. The two reviewers independently and in duplicate abstracted data on the predefined variables on an Excel sheet and resolved any conflicts in scheduled biweekly meetings. Extracted data included the following items: author, year of publication, journal, study design, patient demographics, method of diagnosis, baseline frequency of SBM and BSS for stool type, total number of patients originally assigned to each intervention arm, interventions and comparators used including preparations, dose, administration regime, rescue therapy used, and outcomes (length of follow-up, frequency of SBM, frequency of SBM with straining, BSS for stool type, need for rescue laxatives, and number and type of adverse events associated with treatment).

2.4. Assessment of Risk of Bias (RoB) in Included Studies. When studies met the inclusion criteria, additional data were extracted to specifically assess the following Cochrane RoB 2.0 [42] domains: (1) adequate random sequence generation
Table 1: Eligibility criteria for studies included in the systematic review.

| Types of Studies | Randomized controlled trials with no language restriction  
|------------------|---------------------------------------------------------------|
| Excluded secondary reports and conference proceedings or abstracts without sufficient information, review articles and editorials

| Types of participants | Included: any age, chronic or new diagnosis of FC or IBS-C using Rome IV criteria, patient report of assessment by a physician or investigator  
|-----------------------|------------------------------------------------------------------------------------------------------------------------------------|
| Excluded: participants with constipation secondary to an underlying condition such as Hirschsprung’s disease, prior bowel surgery, hypothyroidism, inflammatory bowel disease, or celiac disease

| Type of interventions and comparators | Interventions: kiwifruit, kiwifruit-extracts or supplements containing kiwifruit or its enzyme actinidin, given in any form by mouth (whole fruit, capsules, chewable tablets, or powder) and at any dose for any duration of time  
|--------------------------------------|------------------------------------------------------------------------------------------------------------------------------------|
| Comparators: any non-kiwifruit oral laxative or placebo or no treatment

| Types of outcome measures | (i) Frequency of spontaneous and/or complete bowel movements (defined as a bowel movement that is spontaneous without any rescue laxatives, suppositories, enemas or other physical assistance, and leaves a feeling of complete evacuation)  
|--------------------------|------------------------------------------------------------------------------------------------------------------------------------|
| (ii) Stool consistency according to the Bristol Stool Scale (scale range is 1-7, where 1 is hardest stools and 7 is diarrhea)  
| (iii) Frequency of straining with bowel movement  
| (iv) Relief of abdominal pain  
| (v) Proportion of bowel urgency or tenesmus  
| (vi) Frequency of rescue laxatives used  
| (vii) Rome diagnostic criteria for FC or IBS-C measured at baseline and at time primary outcome is assessed  
| (viii) Adverse events reported (e.g., bloating, nausea, vomiting, allergic reactions)

Figure 1: Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow diagram.
and allocation concealment; (2) masking, deviations from intended intervention, and intention to treat analysis participant; (3) missing outcome data; (4) measurement of the outcome; (5) selective reporting of the results. We used the modified Cochrane RoB 2.0 for crossover trials. A pair of reviewers (M. E., R. L.) independently assessed the articles for RoB. Response options for each item were “yes,” “probably yes,” “no,” “probably no,” and “no information.” Assignment of the final RoB assessment as “high,” “low,” or “some concerns” was done through RoB 2.0 Cochrane algorithm. If assessors’ judgment differed and consensus after a discussion was not reached, a third author (E. R.) adjudicated.

2.5. Assessment of Certainty of Evidence. We used the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach [43] for rating the certainty of the evidence of all outcomes. We rated down the certainty based on serious (rated down by 1) or very serious (rated down by 2) concerns for the following: (1) RoB if there were overall serious or very serious concerns (not rated down if sensitivity analysis did not show an effect on overall estimates); (2) if the results were inconsistent based on inspection of the forest plot and heterogeneity; (3) if the trials included for the outcome of interest did not provide direct evidence for our research question; (4) if the results were imprecise based on total sample size <400 observations for continuous outcomes and if 95% confidence intervals (CI) excluded the null effect; (5) publication bias assessed through a funnel plot (if more than ten trials included) and by searching trial registries for unpublished trials.

2.6. Measures of Treatment Effect. Studies reporting on the weekly or daily frequency of SBM were pooled separately, and a mean difference (MD) with 95% CI was calculated. If studies reported on different outcome measurement scales and we were not able to impute the results on a common scale, a standardized mean difference (SMD) was calculated with a corresponding 95% CI. For dichotomous outcomes, like adverse events, we calculated a risk ratio (RR) and corresponding 95% CI. There was no established anchor-based minimally important difference (MID) for the outcomes chosen. Most clinicians and previous trials [36] used an increase of at least one weekly SBM as the MID.

2.7. Assessment of Heterogeneity. Heterogeneity was assessed by visual inspection of forest plots and by calculating the chi-squared test. A p-value for heterogeneity of <0.05 was considered significant. We also employed the $I^2$ statistic to assess heterogeneity quantitatively. An $I^2$ statistic of 0–40% might not be important, 30–60% represents moderate heterogeneity, 50–90% represents substantial heterogeneity, and 75–100% represents considerable heterogeneity. We assessed reasons for heterogeneity, and a sensitivity analysis was conducted if a single study was found to account for the majority.

2.8. Data Synthesis and Analysis. We decided a priori to analyze continuous data with a random-effects model since we expected the treatment effect would vary across studies (e.g., the effect might differ on patients with FC compared to IBS-C). We used the inverse variance to pool effect measures across continuous outcomes and Mantel–Haenszel to pool dichotomous outcomes with few events, such as adverse events. We used RevMan (Review Manager Version 5.3) [44] to perform a meta-analysis and generate forest plots. We presented our outcomes in a summary of findings table as recommended in the Cochrane Handbook for Systematic Reviews of Interventions. This was generated through GRADEPro Guideline Development Tool web-based software.

2.9. Subgroup and Sensitivity Analysis and Investigation of Heterogeneity. We planned to conduct the following subgroup analyses a priori, pediatric vs. adult participants and high RoB vs. low RoB. Depending on the results and the heterogeneity found between studies, we conducted an exploratory post hoc sensitivity analysis by excluding any studies with a large treatment effect and high RoB.

3. Results

3.1. Results of the Search. We identified 452 citations using the search strategy and removed 184 duplicates. After screening 268 abstracts, we retrieved 37 full-text articles to assess for eligibility (Figure 1: PRISMA flowchart). We included seven RCTs [16, 24, 25, 31, 32, 45, 46] with 399 participants. One study [46] was only reported as an abstract but had enough data on the frequency of SBM to be included. All included studies were small and individual study sample sizes ranged from 9 [16] to 120 [46] participants. All studies recruited ambulatory care patients or volunteers through advertisements. The pooled mean age (from studies reporting age) [16, 24, 25, 31, 32, 45] was 42 years (standard deviation (SD) 14.6), pooled pooled mean weight was 62.5 kg (SD 19.2), and 82% were female (from 205/250 studies that reported gender). [16, 24, 25, 31, 45] On average across studies, baseline SBM was 2/week (SD 0.9). Four studies [16, 25, 31, 32] used encapsulated kiwifruit extracts with varying doses and three studies [24, 45, 46] used the whole kiwifruit. Four studies used placebo [16, 25, 31, 32] as a comparator and three used psyllium [24, 45, 46] as a fibre-based laxative. Given how different a placebo is from an active comparator, we performed meta-analysis and pooled results of trials that used placebo separately from trials that had an active comparator (psyllium). Duration of follow-up ranged from 2 to 16 weeks. Four studies were crossover [16, 24, 25, 46] and three were parallel-group [31, 32, 45] RCTs (Table 2: Study Characteristics).

3.2. Outcomes Reported. The most consistent outcomes reported were weekly or daily frequency of SBM or completed SBM, BSS, abdominal pain score, and frequency of straining. Only two studies had rescue therapy or other laxative use as an outcome, and only one provided results that showed no increase in rescue laxative
## Table 2: Study characteristics.

| Study/Design/Population | Population | Intervention | Outcomes |
|-------------------------|------------|--------------|----------|
| **Weir 2018**           | Adults ≥18 yrs. | Parallel-group double-blind RCT* | 14 |
|                         | Age range: 23 to 65 | Placebo capsules containing the same color isomalt at the same frequency as an intervention | (i) SBM† (ii) Modified BSS§ (score 1–3) (iii) Abdominal pain (iv) Adverse events (nonreported) |
|                         | Not reported | 2.2 (0.8) | Zyactinase capsules 2160 mg/day given as 720 mg tid |
|                         | Not reported | Encapsulated kiwifruit extracts containing skin, flesh, and seeds, 1000 mg/day given as 500 mg bid |
| **Kindleysides 2015**   | Adults ≥18 yrs. | Crossover double-blind RCT* | 21 |
|                         | Age: 40.8 (13.2) | Placebo was encapsulated magnesium stearate matched for weight, color, and size given at the same frequency as intervention | (i) SBM† (ii) BSS§ (iii) GSRS (iv) Adverse events |
|                         | Weight 68 (14.7) | 2.4 (0.1) | Encapsulated kiwifruit containing high dose Actazin 2400 mg/day given as 600 mg qid |
|                         | Female (93%) | Female (89%) | Rome III FC criteria |
| **Ansell 2015**         | Adults ≥18 yrs. | Crossover double-blind RCT* | 28 |
|                         | Age: 44 (6) | Placebo capsules containing isomalt at the same frequency as intervention | (i) SBM† (ii) BSS§ (iii) Frequency of SBM† with straining (iv) Incomplete evacuation (v) Bloating (vi) Flatulence (vii) IBS-C‡ (viii) QoL questionnaire |
|                         | Weight: 67 (8) | 3.5 (2.2) Kiwifruit, 2 fruits/day | Kivia powder containing zyactinase 5500 mg/day given once daily in a sachet |
|                         | Female (89%) | Placebo was powder containing inactive compounds in identical sachet to kivia given same frequency as intervention |
| **Udani 2013**          | Adults ≥18 yrs. | Parallel-group double-blind placebo-controlled RCT* | 28 |
|                         | Age: 39.3 (13.8) | Placebo was powder containing inactive compounds in identical sachet to kivia given same frequency as intervention | (i) CSBM◊ (ii) BSS§ (iii) Abdominal pain (iv) Bloating (v) Flatulence (vi) Satisfaction with bowel habits (vii) Use of rescue laxatives (viii) Adverse events |
|                         | Weight: 73.5 (14.1) | 2.1 (0.6) | Kivia powder containing zyactinase 5500 mg/day given once daily in a sachet |
|                         | Female (64%) | Rome III FC criteria |
| **Barbara 2018**        | Adults ≥18 yrs. | Crossover, single-blind 3-centre RCT* | 14 |
|                         | Not reported | Placebo capsules containing the same color isomalt at the same frequency as an intervention | (i) SBM† (ii) BSS§ (iii) GSRS IBS-C‡ QoL questionnaire |
|                         | 3.5 (2.2) Kiwifruit, 2 fruits/day | Psyllium 7.5 grams/day |

*SD* = standard deviation; *RCT* = randomized controlled trial; *SBM* = spontaneous bowel movements; *BSS* = Bristol stool scale; *CSBM* = computerized spontaneous bowel movements; *QoL* = quality of life; *IBS-C* = irritable bowel syndrome with constipation; *FC* = functional constipation; *GSRS* = Graded Severity Rating Scale; *†* = Modified BSS; *§* = Modified BSS; *◊* = Computerized SBM; *‡* = Rome III FC criteria.

**Notes:**
- *N* is the total number of participants for each study.
- Interventions are described as follows:
  - Zyactinase capsules: 2160 mg/day given as 720 mg tid.
  - Encapsulated kiwifruit extracts: 1000 mg/day given as 500 mg bid.
  - Encapsulated kiwifruit extracts: 2400 mg/day given as 600 mg qid.
  - Kivia powder: containing zyactinase 5500 mg/day given once daily in a sachet.
  - Psyllium: 7.5 grams/day.
- Outcomes include:
  - (i) SBM†
  - (ii) Modified BSS§ (score 1–3)
  - (iii) Abdominal pain
  - (iv) Adverse events
  - (v) Bloating
  - (vi) Flatulence
  - (vii) IBS-C‡ (viii) QoL questionnaire
  - (ix) Functional constipation
  - (x) Computerized SBM
  - (xi) Modified BSS
  - (xii) Abdominal pain
  - (xiii) Bloating
  - (xiv) Flatulence
  - (xv) IBS-C‡ (xvi) QoL questionnaire
  - (xvii) Functional constipation
  - (xviii) Computerized SBM
  - (xix) Modified BSS
  - (xx) Abdominal pain
  - (xxi) Bloating
  - (xxii) Flatulence
  - (xxiii) IBS-C‡ (xxiv) QoL questionnaire
  - (xxv) Functional constipation
  - (xxvi) Computerized SBM
  - (xxvii) Modified BSS
  - (xxviii) Abdominal pain
  - (xxix) Bloating
  - (xxx) Flatulence
  - (xxxi) IBS-C‡ (xxxii) QoL questionnaire
  - (xxxiii) Functional constipation
  - (xxxiv) Computerized SBM
  - (xxxv) Modified BSS
  - (xxxvi) Abdominal pain
  - (xxxvii) Bloating
  - (xxxviii) Flatulence
  - (xxxix) IBS-C‡ (xxxx) QoL questionnaire
  - (xxxxi) Functional constipation
  - (xxxxii) Computerized SBM
  - (xxxxiii) Modified BSS
  - (xxxxiv) Abdominal pain
  - (xxxxv) Bloating
  - (xxxxvi) Flatulence
  - (xxxxvii) IBS-C‡ (xxxxviii) QoL questionnaire
  - (xxxxix) Functional constipation
  - (xxxxx) Computerized SBM
  - (xxxxxi) Modified BSS
  - (xxxxxii) Abdominal pain
  - (xxxxxiii) Bloating
  - (xxxxxiv) Flatulence
  - (xxxxxv) IBS-C‡ (xxxxxvi) QoL questionnaire
  - (xxxxxx) Functional constipation
  - (xxxxxxi) Computerized SBM
  - (xxxxxxii) Modified BSS
  - (xxxxxxiii) Abdominal pain
  - (xxxxxxiv) Bloating
  - (xxxxxxv) Flatulence
  - (xxxxxxvi) IBS-C‡ (xxxxxxvii) QoL questionnaire
  - (xxxxxxviii) Functional constipation
  - (xxxxxxix) Computerized SBM
  - (xxxxxxxi) Modified BSS
  - (xxxxx...
use [16]. Two studies reported adverse events [25, 31]. One study used a modified BSS, [32] collapsing the 7 categories of the scale to only 3 and reversing the order of severity (1 is soft stools and 3 is very hard stool), while all other studies used the 7-point BSS.

3.3. RoB in Included Studies. Across all outcomes, most studies had some concerns or were high RoB (Figure 2). We used the algorithm provided by Cochrane to determine the overall RoB for each study’s outcome. We used overall RoB for each outcome for GRADE and presented these results in Tables 3 and 4. We were not able to construct a funnel plot to assess for publication bias since we only had seven studies.

3.4. Frequency of Bowel Movements. The frequency of SBM was reported in all studies included. We pooled studies reporting weekly frequency [25, 32] separately from studies that reported daily frequency of SBM [16, 31]. In two studies with 95 participants (one crossover [25] and one parallel-group RCT [32]) comparing kiwifruit to placebo, we found a mean increase of 1.36 weekly SBM favoring kiwifruit (95% CI [0.43 decrease to 3.16 increase in weekly SBM]) with low certainty of evidence (Figure 3(a), Table 3). Two studies [16, 31] (one crossover [16] and one parallel-group RCT [31]) with 91 participants comparing kiwifruit to placebo did not show a meaningful clinical difference in frequency of daily SBM, with moderate certainty of evidence (Figure 3(b), Table 3). When comparing kiwifruit (fruit or extracts) to psyllium in three studies (two crossover RCTs and one parallel-group RCT) of 200 participants [24, 45], there was a mean increase of 1.01 weekly SBM (95% CI (0.02 decrease to 2.04 increase in SBM)) with moderate certainty of evidence (Figure 4(a), Table 4).

3.5. Bristol Stool Scale. Three of the four placebo-controlled studies, including 150 participants, reported BSS scores. When comparing kiwifruit to placebo, there was an SMD of 1.54 (95% CI: 1.33 lower to 4.41 higher) on the BSS, albeit with very low certainty of evidence (Figure 3(c), Table 3). Reasons for downgrading certainty included serious concerns with RoB, very high heterogeneity, small sample size, and a wide CI that includes the null and possible harm (worsening in BSS). In the two studies of 83 participants [24, 45] comparing kiwifruit to psyllium, participants who received kiwifruit had

| Population | Study/Design/Population | Age years (SD) | Weight mean (standard deviation) kg | Baseline weekly frequency of spontaneous bowel movements (standard deviation) | Intervention/dose/duration | Intervention | Study follow-up period in days | Outcomes |
|------------|------------------------|----------------|------------------------------------|----------------------------------|---------------------------|-------------|-----------------------------|----------|
| Eady 2019  | Adults ≥18 yrs.        | Age: 47 (12.9) | Weight 67.5 (14.4) Female (100%) | Rome III: (i) FC (29%) (ii) IBS-c (71%) Age 44.9 (16.8) Weight: NR Female (87%) | 3.0 (1.6) Kiwifruit, 3 fruits daily | Metamucil 2.5 teaspoons (5 g of fibre total) daily | 45         | (i) CSBM⁶ (ii) BSS⁵ (iii) GSRS (iv) Rome III classification |
| Chey 2021  | Adults ≥18 yrs.        | Rome III: (i) FC (71%) (ii) IBS-C (33%) | 1.2 (1.5) 2 green kiwifruit daily (Actinidia deliciosa var. Hayward, fibre 6 g/day) | 12 g of psyllium daily | | | 28 | (i) CSBM⁶ responder rate defined as ≥1 CSBM⁶/week (ii) CSBM⁶ and SMB frequency (iii) BSS (iv) frequency of straining (v) abdominal pain (vi) bloating (vii) adverse events |

⁵CSBM = complete spontaneous bowel movement, GSRS = gastrointestinal symptom rating scale for abdominal pain, ⁶RCT = randomized controlled trial, ⁷SBM = spontaneous bowel movement, ⁸FC = functional constipation, ⁹IBS-C = irritable bowel syndrome with constipation, ⁹BSS = Bristol Stool Chart.
A higher score on the BSS (softer stool), with a mean difference of 0.63 (95% CI (0.01 higher to 1.25 higher)), with low certainty of evidence (Figure 4(b), Table 4).

### 3.6. Abdominal Pain

Four studies reported abdominal pain with 186 participants (two parallel and two crossover RCTs). Lower scores indicated clinical improvement. Kiwifruit...
Table 3: Summary of findings table: kiwi compared to placebo for constipation.

| No of studies | Study design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | No. of patients | Kiwi Effect | Placebo Effect | Relative (95% CI) | Certainty | Importance |
|---------------|--------------|--------------|---------------|--------------|-------------|---------------------|----------------|-------------|---------------|----------------|-----------|------------|
| Weekly frequency spontaneous bowel movement (follow-up: range 14 to 28; assessed with: Self-reported) | Randomized trials | Serious<sup>a</sup> | Serious<sup>b</sup> | Not serious | Not serious<sup>c</sup> | 2 | 65 | MD 1.36 number of bowel movements higher (0.44 lower to 3.16 higher) | LOW | CRITICAL |
| Daily frequency of spontaneous bowel movements (follow-up: range 14 days to 28 days; assessed with: self-reported) | Randomized trials | Not serious | Not serious | Not serious | Serious<sup>d</sup> | None | 48 | MD 0.04 daily SBM higher (0.14 lower to 0.22 higher) | MODERATE | CRITICAL |
| Stool type as per Bristol Stool Chart (follow-up: range 14 days to 28 days; assessed with: Bristol Stool Chart; scale from 1 to 7) | Randomized trials | Serious<sup>e</sup> | Serious<sup>f</sup> | Not serious | Serious<sup>g</sup> | None | 74 | SMD 1.54 SD higher (1.33 lower to 4.41 higher) | VERY LOW | IMPORTANT |
| Abdominal pain (follow-up: range 14 days to 30 days; assessed with: abdominal pain scores (variable scores)) | Randomized trials | Not serious<sup>h</sup> | Not serious | Not serious | None | 113 | SMD 1.44 SD lower (2.83 lower to 0.06 lower) | MODERATE | IMPORTANT |
| Straining (follow-up: range 14 days to 30 days; assessed with: different scales) | Randomized trials | Not serious<sup>i</sup> | Not serious | Not serious | Serious<sup>j</sup> | None | 46 | SMD 0.28 SD lower (1.03 lower to 0.47 higher) | MODERATE | IMPORTANT |
| Adverse events (assessed with: number of participants who experienced an adverse event) | Randomized trials | Not serious<sup>k</sup> | Not serious | Not serious | Serious<sup>l</sup> | None | 6/76 | Rate ratio 4.58 (0.79 to 26.40) | LOW | NOT IMPORTANT |

CI: confidence interval; MD: mean difference; SMD: standardized mean difference. (a) Studies with a high risk of bias. (b) We have clinical and methodological heterogeneity in our studies. Most of the confidence intervals do overlap, and the point estimates all favor the intervention. There is high heterogeneity in our pooled analysis, with an I² of 88%. One study (Weir) is responsible for the majority of the inconsistency (I² 0% if excluded). Given the high degree of unexplained heterogeneity, we have rated down for inconsistency by 1. (c) We have rated down for imprecision by 1 for the following reasons: (1) small total sample size of 232 participants, which is lower than our a priori optimal information size of 400 participants and (2) our confidence interval includes the possibility of the null and 0.5. (d) The sample size is <400 participants and the CI crosses the line of no effect. (e) RoB 2.0 for outcome stool type is serious as there are some concerns with randomization and allocation concealment in Kindleysides and Weir. (f) Weir accounts for the inconsistency in the results. Once removed, the P<sub>II</sub> is reduced to 0%. (g) Weir et al. collapsed the Bristol stool chart 7 types of stool to 3 categories which may have resulted in the observed large difference between kiwi and placebo in their study. (g) Total sample size for this outcome is less than 400 h. Interaction test for a subgroup for risk of bias was not significant; therefore, we did not downgrade. (i) P<sub>II</sub> 95% and CI are not overlapping. The heterogeneity is explained by 1 study Weir 2018. They have found a dramatic improvement in abdominal pain scores that was not observed in other studies. (j) CI crosses the line of no effect (SMD 0), small sample size <400. (k) At least one domain is scored as High RoB on RoB 2.0 tool. (l) Very low number of events and wide confidence interval and RR crosses 1.
Table 4: Summary of findings table: kiwi compared to psyllium for constipation.

| Certainty assessment | No of studies | Study design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | Kiwi | Psyllium | Relative (95% CI) | Absolute (95% CI) | Certainty | Importance |
|----------------------|--------------|--------------|--------------|---------------|--------------|-------------|---------------------|------|----------|----------------|-----------------|-----------|------------|
| Weekly frequency of spontaneous bowel movements (higher number indicates an increase frequency) (follow-up: range 14 days to 30 days; assessed with: weekly mean number of SBM) |
| 3 | Randomized trials | Serious a | Not serious b | Not serious | Not serious | None | 178 | 171 | — | MD 1.01 weekly spontaneous bowel movements higher (0.02 lower to 2 higher) | ⊕⊕⊕ | CRITICAL |
| Bristol stool scale (higher number indicates softer stool) (follow-up: range 14 days to 28 days; assessed with BSS 1–7 scale) |
| 2 | Randomized trials | Serious a | Not serious | Not serious | Serious c | None | 61 | 54 | — | MD 0.63 BSS higher (0.01 higher to 1.3 higher) | ⊕⊕ | IMPORTANT |
| Abdominal pain (follow-up: range 14 days to 28 days; assessed with: Abdominal pain scale) |
| 2 | Randomized trials | Serious a | Not serious | Not serious | Serious c,d | None | 61 | 54 | — | SMD 0.16 SD lower (0.6 lower to 0.2 higher) | ⊕⊕ | IMPORTANT |
| Straining frequency (lower number indicates improvement) (follow-up: range 14 days to 28 days; assessed with: weekly frequency of straining) |
| 2 | Randomized trials | Serious a | Not serious | Not serious | Serious | None | 61 | 54 | — | MD 0.2 weekly frequency lower (1.3 lower to 0.9 higher) | ⊕⊕ | IMPORTANT |

CI: confidence interval; MD: mean difference; SMD: standardized mean difference. (a) Chey, 2021, had major issues with randomization and allocation concealment. Included data from abstract published by Barbara, no access to the full article. (b) We did not rate down for inconsistency as some of the elements have been incorporated in rating down of risk of bias and imprecision. (c) Small sample size. (d) Confidence interval is wide, crosses the null, and includes harm.
Figure 3: Forest plots for kiwifruits product vs. placebo. (a) Weekly frequency of spontaneous bowel movements. (b) Daily frequency of spontaneous bowel movements. (c) Bristol stool chart score (higher number indicates softer stool; Weir 2018 is negative as they reversed the scale). (d) Abdominal pain (lower score indicates improved abdominal pain). (e) Straining (lower score indicates less straining). (f) Adverse events (only available for kiwifruits vs. placebo and include bloating).

resulted in improvement in abdominal pain with an SMD that is 1.44 lower (95% CI 2.83 lower to 0.06 lower) than placebo (n = 119), with moderate certainty of evidence (Figure 3(d), Table 3). We did not downgrade for Rob since there was no subgroup effect of low vs. high-risk Rob studies on abdominal pain (Supplement 2). We downgraded by 1 for inconsistency, given a large amount of heterogeneity and the inconsistent result by Weir 2018 [32] that showed a dramatic
improvement in abdominal pain compared to the rest. There was no difference in abdominal pain when comparing kiwifruit with psyllium [24, 45] (n = 83, one crossover and one parallel-group trial) with an SMD of 0.16 lower (95% CI (0.26 lower to 0.24 higher)), with low certainty of evidence (Figure 4(c), Table 4).

3.7. Straining. Two studies [24, 45] with 46 participants (two crossover RCTs) reported the weekly frequency of SBM with straining. Kiwifruit showed a small to moderate effect on straining with an SMD that was 0.28 lower than placebo (95% CI (1.03 lower to 0.47 higher)), with moderate certainty of evidence. We downgraded for imprecision given the small sample size (also explains heterogeneity) and a wide CI that includes varying effect sizes, the null, and harm (higher straining with kiwifruit) (Figure 3(e), Table 3). In the two studies comparing kiwifruit to psyllium [24, 45] with 83 participants (one parallel-group and one crossover trial), there was a small effect on straining favoring kiwifruit with 0.21 fewer episodes of weekly SBM with straining (95% CI (1.28 lower to 0.87 higher)) with low certainty of evidence (Figure 4(d), Table 4).

3.8. Adverse Events. Only two studies [25, 31] that used encapsulated kiwifruit extracts reported adverse events, including flatulence, bloating, nausea, or vomiting. Six participants (6/76) experienced adverse events in the kiwifruit group compared to one in the placebo group (1/80). This resulted in relative risk of 4.58 or 45 more adverse events per 1000 (95% CI (from 3 fewer to 318 more)), with low certainty of evidence.

3.9. Sensitivity and Subgroup Analysis. One study [32] had a substantial effect on heterogeneity of the pooled estimates comparing kiwifruit vs. placebo for SBM, BSS, and abdominal pain. Fourteen participants (19% of the sample size) dropped out of the study without any outcome data, which may have biased the results. We conducted a post hoc sensitivity analysis by excluding Weir 2018 from the pooled result, with the exception of SBM, since there were only two trials for this outcome (Supplement 3). For BSS, heterogeneity decreased from \( I^2 = 97\% \) to 0%, and there was no change in BSS when comparing kiwifruit with placebo. For abdominal pain, heterogeneity decreased from 95% to 27%, and the SMD was reduced to 0.44 (95% CI (0.82 lower to 0.07

Figure 4: Forest plots for kiwifruits product vs. psyllium. (a) Weekly frequency of spontaneous bowel movements. (b) Bristol stool chart score. (c) Abdominal pain (lower number indicates improved abdominal pain). (d) Straining (lower score indicates less straining).
4. Discussion

Compared to placebo, kiwifruit extracts may increase the frequency of weekly SBM (moderate effect, low certainty of evidence), have little to no effect on the daily frequency of SBM (moderate certainty of evidence), and have little to no effect on the daily frequency of SBM (moderate certainty of evidence). Compared to placebo, kiwifruit may increase the frequency of weekly SBM (small important effect, moderate certainty of evidence), improve stool consistency (small important effect, low certainty of evidence), and result in little to no difference in abdominal pain and straining (trivial small effect, low certainty of evidence). Compared to placebo, kiwifruit and extracts may result in increased minor adverse events, such as bloating, flatulence, and nausea.

To our knowledge, this is the first systematic review and meta-analysis to examine the effect of kiwifruit on patients with FC or IBS-C. Although results are promising, the overall literature reflects a low certainty of evidence. As a fruit and source of fibre, there are no apparent drawbacks in adding kiwifruit to the diet, with the caveat that additional laxatives may be needed if there is no response. These findings may not be generalizable to children (not included), males (most participants were females), or severe FC (most studies only included occasional or mild FC).

The first line therapy for both FC and IBS-C in adults is bulking agents, specifically fibre; the addition of osmotic laxatives is recommended for FC but not for IBS-C [7, 9, 47]. Psyllium has been shown effective in the management of chronic constipation [48], with further meta-analyses concluding that fibre is effective in chronic idiopathic constipation [49] and IBS [9]. The potential for kiwifruit and kiwifruit extracts to be either slightly more effective or noninferior to psyllium is compelling, given the predominant role of fibre in the initial management of both FC and IBS-C. The adverse events reported with kiwifruit extracts are in line with other non-food-based laxatives and may be supportive of active laxative effects [50].

The mechanisms of action of kiwifruit are an area of ongoing investigation. In addition to being a source of soluble and insoluble fibre, kiwifruit contain antioxidants, phytonutrients, and enzyme actinidin [27]. The actions of actinidin have been linked to digestive health, with studies suggesting that actinidin can enhance the digestion of meat proteins, dairy, and wheat (which have all been associated with IBS symptomatology) and also accelerate gastric emptying [51–53]. Given that alterations in the gut microbiota have been implicated in the pathogenesis of constipation and IBS [54–56], there has been considerable interest in the potential for kiwifruit to also act on the microbiome. For example, kiwifruit has been shown to promote the growth of beneficial microbiota for gut health, including lactobacilli and bifidobacteria [57], and also to influence the production and absorption of short-chain fatty acids [53].

Our review had several strengths and limitations. We preregistered our protocol prior to commencing data abstraction, adhered to our predefined eligibility criteria, had no language or age restrictions, and included studies reporting any outcomes. Our search was comprehensive, spanning several large databases and registries, and we used piloted screening and data abstraction forms independently and in duplicate. We assessed RoB for each outcome as per the recommendations in Cochrane Handbook for Systematic Reviews of Interventions and assessed the certainty of evidence using GRADE. There was significant heterogeneity in the trials included due to differences in design, intervention, and population, and we addressed the heterogeneity by conducting a sensitivity analysis. In addition, we were unable to perform some preplanned subgroup analyses due to a lack of sufficient information or studies, and many of our outcomes were of low certainty of evidence with low-to-moderate effect sizes.

5. Conclusion

Among individuals with constipation, low certainty of evidence indicates that kiwifruit may increase stool frequency and improve abdominal pain and straining when compared to placebo. Kiwifruit may improve stool frequency and improve consistency when compared to psyllium. Our findings are limited by significant heterogeneity and high RoB across trials included. Large, well-designed parallel-group RCTs comparing kiwifruit or kiwifruit extracts with known conventional and effective therapies are needed to further explore the role of kiwifruit products in the treatment of constipation.

Data Availability

The data that support the findings of this study can be obtained from the corresponding author upon reasonable request.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

M.E. and E.R. conceptualized the research question and formalized the study plan. M.E., R.L., and E.R. wrote the study protocol, conducted the literature search, screened articles, and abstracted data. M.E. conducted the analysis and wrote the first draft of the manuscript that was reviewed and edited by R.L. and E.R. All authors approved the final draft submitted. Dr. Eltorki accepts full responsibility for the conduct of the study. He has access to the data and made the decision to publish it.
Acknowledgments

The authors would like to thank our librarian Denise Smith (McMaster Faculty of Health Sciences librarian) and Dr. Nancy Santesso (Associate Professor at McMaster University Department of Health Research Methods, Evidence, and Impact) for their guidance in the literature search and the meta-analysis.

Supplementary Materials

Supplement 1: Search Strategy. Supplement 2: Abdominal pain (kiwi vs. placebo); with risk of bias (RoB) subgroups. Supplement 3: Sensitivity analysis. (a) Bristol Stool Chart score; higher number indicates softer stool; (b) Abdominal pain (lower number indicates improved abdominal pain).

https://academic.oup.com/jcag/article/5/Supplement_1/133/6533030?login=false. (Supplementary Materials)

References

[1] R. M. Lovell and A. C. Ford, "Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis," *Clinical Gastroenterology and Hepatology*, vol. 10, no. 7, pp. 712–721.e4, 2012.

[2] A. F. Peery, S. D. Crockett, C. C. Murphy et al., "Burden and cost of gastrointestinal, liver, and pancreatic diseases in the United States: update 2018," *Gastroenterology*, vol. 156, no. 1, pp. 254–272.e11, 2019.

[3] A. Frandemark, H. Tornblom, S. Jakobsson, and M. Simren, "Work productivity and activity impairment in irritable bowel syndrome (IBS): a multifaceted problem," *American Journal of Gastroenterology*, vol. 113, no. 10, pp. 1540–1549, 2018.

[4] J. A. Doshi, Q. Cai, J. L. Buono et al., "Economic burden of irritable bowel syndrome with constipation: a retrospective analysis of health care costs in a commercially insured population," *Journal of Managed Care Pharmacy*, vol. 20, no. 4, pp. 382–390, 2014.

[5] N. C. Suares and A. C. Ford, "Prevalence of, and risk factors for, chronic idiopathic constipation in the community: systematic review and meta-analysis," *American Journal of Gastroenterology*, vol. 106, no. 9, pp. 1582–1591, 2011.

[6] H. The Lancet Gastroenterology, "The cost of constipation," *The Lancet Gastroenterology & Hepatology*, vol. 4, no. 11, p. 811, 2019.

[7] F. Mearin, B. E. Lacy, and L. Chang, "Bowel disorders," *Gastroenterology*, vol. 150, 2016.

[8] P. Luthra, M. Camilleri, N. E. Burr, E. M. M. Quigley, C. J. Black, and A. C. Ford, "Efficacy of drugs in chronic idiopathic constipation: a systematic review and network meta-analysis," *The Lancet Gastroenterology & Hepatology*, vol. 4, no. 11, pp. 831–844, 2019.

[9] P. Moayyedi, C. N. Andrews, G. MacQueen et al., "Canadian association of gastroenterology clinical practice guideline for the management of irritable bowel syndrome (IBS)," *Journal of the Canadian Association of Gastroenterology*, vol. 2, no. 1, pp. 6–29, 2019.

[10] J. F. Johanson and J. Kralstein, "Chronic constipation: a survey of the patient perspective," *Alimentary Pharmacology & Therapeutics*, vol. 25, no. 5, pp. 599–608, 2007.

[11] M. A. van Tilburg, O. S. Palsson, R. L. Levy et al., "Complementary and alternative medicine use and cost in functional bowel disorders: a six month prospective study in a large HMO," *BMC Complementary and Alternative Medicine*, vol. 8, no. 1, p. 46, 2008.

[12] N. R. Santucci, A. Chogle, A. Leiby et al., "Non-pharmacologic approach to pediatric constipation," *Complementary Therapies in Medicine*, vol. 59, Article ID 102711, 2021.

[13] E. D. Shah, J. K. Salwen-Deremer, P. R. Gibson, J. G. Muir, S. Eswaran, and W. D. Chey, "Pharmacologic, dietary, and psychological treatments for irritable bowel syndrome with constipation: cost utility analysis," *MDM Policy & Practice*, vol. 6, no. 1, Article ID 238146832097841, 2021.

[14] J. L. Anderson, L. Oliveira & Silva, S. A. Funni, F. Bellolio, and M. M. Jeffery, "Epidemiology of paediatric pain-related visits to emergency departments in the USA: a cross-sectional study," *BMJ Open*, vol. 11, no. 8, Article ID e046497, 2021.

[15] P. Singh, C. Tuck, P. R. Gibson, and W. D. Chey, "The role of food in the treatment of bowel disorders: focus on irritable bowel syndrome and functional constipation," *American Journal of Gastroenterology*, vol. 117, no. 6, pp. 947–957, 2022.

[16] J. Ansell, C. A. Butts, G. Paturi et al., "Kiwifruit-derived supplements increase stool frequency in healthy adults: a randomized, double-blind, placebo-controlled study," *Nutrition Research*, vol. 35, no. 5, pp. 401–408, 2015.

[17] S. B. Bayer, R. B. Gearry, and L. N. Drummond, "Putative mechanisms of kiwifruit on maintenance of normal gastrointestinal function," *Critical Reviews in Food Science and Nutrition*, vol. 58, no. 14, pp. 2432–2452, 2018.

[18] K. L. Bentley-Hewitt, P. A. Blatchford, S. G. Parkar, J. Ansell, and A. Pernthaner, "Digested and fermented green kiwifruit increases human beta-defensin 1 and 2 production in vitro," *Plant Foods for Human Nutrition*, vol. 67, no. 3, pp. 208–214, 2012.

[19] P. Blatchford, H. Stoklosinski, S. Eady et al., "Consumption of kiwifruit capsules increases Faecalibacterium prausnitzii abundance in functionally constipated individuals: a randomised controlled human trial," *Journal of Nutrition Sciences*, vol. 6, p. e52, 2017.

[20] A. O. O. Chan, G. Leung, T. Tong, and N. Y. Wong, "Increasing dietary fiber intake in terms of kiwifruit improves constipation in Chinese patients," *World Journal of Gastroenterology*, vol. 13, no. 35, pp. 4771–4775, 2007.

[21] C. C. Chang, Y. T. Lin, Y. T. Lu, Y. S. Liu, and J. F. Liu, "Kiwifruit improves bowel function in patients with irritable bowel syndrome with constipation," *Asia Pacific Journal of Clinical Nutrition*, vol. 19, no. 4, pp. 451–457, 2010.

[22] A. G. Y. Chen, M. S. L. Offereins, C. J. Mulder, Z. Eady, K. R. Thompson, and A. Pernthaner, "Digested and fermented green kiwifruit increases human beta-defensin 1 and 2 abundance in functionally constipated individuals: a randomised controlled human trial," *Journal of Nutrition Sciences*, vol. 11, no. 8, e046497, 2021.

[23] E. D. Shah, J. K. Salwen-Deremer, P. R. Gibson, J. G. Muir, S. Eswaran, and W. D. Chey, "Pharmacologic, dietary, and psychological treatments for irritable bowel syndrome with constipation: cost utility analysis," *MDM Policy & Practice*, vol. 6, no. 1, Article ID 238146832097841, 2021.
micrObial populations,” *Plant Foods for Human Nutrition*, vol. 67, no. 3, pp. 200–207, 2012.

[27] D. P. Richardson, J. Ansell, and L. N. Drummond, “The nutritional and health attributes of kiwifruit: a review,” *European Journal of Nutrition*, vol. 57, no. 8, pp. 2659–2676, 2018.

[28] E. C. Rush, M. Patel, L. D. Plank, and L. R. Ferguson, “Kiwifruit promotes lactation in the elderly,” *Asia Pacific Journal of Clinical Nutrition*, vol. 11, no. 2, pp. 164–168, 2002.

[29] M. A. Skinner, J. M. S. Loh, C. A. Conlon, M. A. Skinner, J. M. S. Loh, D. C. Hunter, and J. Zhang, “Gold kiwifruit (Actinidia chinensis Hort16A) for immune support,” *Proceedings of the Nutrition Society*, vol. 70, no. 2, pp. 276–280, 2011.

[30] W. Stonehouse, C. S. Gammon, K. L. Beck, C. A. Conlon, P. R. von Hurst, and R. Kruger, “Kiwifruit: our daily prescription for health,” *Canadian Journal of Physiology and Pharmacology*, vol. 91, no. 6, pp. 442–447, 2013.

[31] J. K. Udani and D. W. Bloom, “Effects of Kivita powder on gut health in patients with occasional constipation: a randomized, double-blind, placebo-controlled study,” *Nutrition Journal*, vol. 12, no. 1, p. 78, 2013.

[32] I. Weir, Q. Shu, N. Wei, C. Wei, and Y. Zhu, “Efficacy of actinidin-containing kiwifruit extract Zyactinase on constipation: a randomised double-blinded placebo-controlled clinical trial,” *Asia Pacific Journal of Clinical Nutrition*, vol. 27, no. 3, pp. 564–571, 2018.

[33] V. Wilkinson-Smith, N. Dellschaft, J. Ansell et al., “Mechanisms underlying effects of kiwifruit on intestinal function shown by MRI in healthy volunteers,” *Alimentary Pharmacology and Therapeutics*, vol. 49, no. 6, pp. 759–768, 2019.

[34] R. Wilson, J. Willis, R. B. Garry et al., “SunGold kiwifruit supplementation of individuals with prediabetes alters gut microbiota and improves vitamin C status, anthropometric and clinical markers,” *Nutrients*, vol. 10, no. 7, p. 895, 2018.

[35] R. W. Chapman, V. Stanghellini, M. Geraint, and M. Halphen, “Randomized clinical trial: macrogol/PEG 3350 plus electrolytes for treatment of patients with constipation associated with irritable bowel syndrome,” *American Journal of Gastroenterology*, vol. 108, no. 9, pp. 1508–1515, 2013.

[36] A. J. Lenbo, H. A. Schneier, S. J. Shiff et al., “Two randomized trials of linaclotide for chronic constipation,” *New England Journal of Medicine*, vol. 365, no. 6, pp. 527–536, 2011.

[37] D. Candy and I. Belsey, “Macrogol (polyethylene glycol) laxatives in children with functional constipation and faecal impaction: a systematic review,” *Archives of Disease in Childhood*, vol. 94, no. 2, pp. 156–160, 2008.

[38] M. Gordon, K. Naidoo, A. K. Akobeng, and A. G. Thomas, “Cochrane Review: osmotic and stimulant laxatives for the management of childhood constipation (Review),” *Evidence-Based Child Health*, vol. 8, no. 1, pp. 57–109, 2013.

[39] S. Kuizenga-Wessel, N. F. Steutel, M. A. Benninga et al., “Development of a core outcome set for clinical trials in childhood constipation: a study using a Delphi technique,” *BMJ Paediatrics Open*, vol. 1, no. 1, Article ID e000017, 2017.

[40] I. J. N. Koppen, M. Saps, J. V. Lavigne et al., “Recommendations for pharmacological clinical trials in children with functional constipation: the Rome foundation pediatric subcommittee on clinical trials,” *Neuro-Gastroenterology and Motility*, vol. 30, no. 4, Article ID e13294, 2018.

[41] “Covidence Systematic Review Software VHI;” https://www.covidence.org.

[42] J. A. C. Sterne, J. Savovic, M. J. Page et al., “RoB 2: a revised tool for assessing risk of bias in randomised trials,” *BMJ*, vol. 366, p. e14989, 2019.

[43] G. H. Guyatt, A. D. Oxman, G. E. Vist et al., “GRADE: an emerging consensus on rating quality of evidence and strength of recommendations,” *BMJ*, vol. 336, no. 7650, pp. 924–926, 2008.

[44] L. Schmidt, F. Shokran, K. Steinhausen, and C. E. Adams, “Introducing RAPTORS: RevMan parsing tool for reviewers,” *Systematic Reviews*, vol. 8, no. 1, p. 151, 2019.

[45] S. W. Chey, W. D. Chey, K. Jackson, and S. Eswaran, “Exploratory comparative effectiveness trial of green kiwifruit, psyllium, or prunes in US patients with chronic constipation,” *Official Journal of the American College of Gastroenterology | AGC*, vol. 116, 2021.

[46] G. F. S. Barbata, S. Fukudo, L. Drummond, B. Kuhn-Sherlock, J. Ansell, and R. Garry, “Tu1644 - green kiwifruit compared to psyllium for the relief of constipation and improving digestive comfort in patients with functional constipation and constipation predominant irritable bowel syndrome — analysis of three international trial centres,” *Gastroenterology*, vol. 154, no. 6, pp. S-979–S-980, 2018.

[47] J. Serra, D. Pohl, F. Arpin et al., “Europe neuropathic Gastroenterology and Motility guidelines on functional constipation in adults,” *Neuro-Gastroenterology and Motility: The Official Journal of the European Gastrointestinal Motility Society*, vol. 32, no. 2, Article ID e13762, 2020.

[48] W. Ashraf, F. Park, J. Lof, and E. M. M. Quigley, “Effects of psyllium therapy on stool characteristics, colon transit and ano-rectal function in chronic idiopathic constipation,” *Alimentary Pharmacology & Therapeutics*, vol. 9, no. 6, pp. 639–647, 2007.

[49] S. Christoudoulides, E. Dimidi, K. C. Fragkos, A. D. Farmer, K. Whelan, and S. M. Scott, “Systematic review with meta-analysis: effect of fibre supplementation on chronic idiopathic constipation in adults,” *Alimentary Pharmacology & Therapeutics*, vol. 44, no. 2, pp. 103–116, 2016.

[50] P. Pare and R. N. Fodorak, “Systematic review of stimulant and nonstimulant laxatives for the treatment of functional constipation,” *Canadian Journal of Gastroenterology and Hepatology*, vol. 28, no. 10, pp. 549–557, 2014.

[51] C. A. Montoya, S. M. Rutherford, T. D. Olson et al., “Actinidin from kiwifruit (Actinidia delicosa cv. Hayward) increases the digestion and rate of gastric emptying of meat proteins in the growing pig,” *British Journal of Nutrition*, vol. 111, no. 6, pp. 957–967, 2014.

[52] C. A. Montoya, J. P. Hindmarsh, L. Gonzalez, M. J. Boland, P. J. Moughan, and S. M. Rutherford, “Dietary actinidin from kiwifruit (Actinidia delicosa cv. Hayward) increases gastric digestion and the gastric emptying rate of several dietary proteins in growing rats,” *Journal of Nutrition*, vol. 144, no. 4, pp. 440–446, 2014.

[53] C. A. Montoya, S. M. Rutherford, and P. J. Moughan, “Kiwifruit fibre level influences the predicted production and absorption of SCFA in the hindgut of growing pigs using a combined in vivo-in vitro digestion methodology,” *British Journal of Nutrition*, vol. 115, no. 8, pp. 1317–1324, 2016.

[54] D. Avelar Rodriguez, J. Popov, E. M. Ratcliffe, and E. M. Toros Monjaraz, “Functional constipation and the gut microbiome in children: preclinical and clinical evidence,” *Front Pediatr*, vol. 8, Article ID 595531, 2020.
[55] G. Parthasarathy, J. Chen, X. Chen et al., "Relationship between microbiota of the colonic mucosa vs. feces and symptoms, colonic transit, and methane production in female patients with chronic constipation," *Gastroenterology*, vol. 150, no. 2, pp. 367–379.e1, 2016.

[56] J. Tap, M. Derrien, H. Tornblom et al., "Identification of an intestinal microbiota signature associated with severity of irritable bowel syndrome," *Gastroenterology*, vol. 152, no. 1, pp. 111–123.e8, 2017.

[57] Y. K. Lee, K. Y. Low, K. Siah, L. M. Drummond, and K. A. Gwee, "Kiwi fruit (Actinidia deliciosa) changes intestinal microbial profile," *Microbial Ecology in Health and Disease*, vol. 23, no. 0, 2012.